Analyst Price Target is $106.80
▲ +66.61% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Inari Medical in the last 3 months. The average price target is $106.80, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 66.61% upside from the last price of $64.10.
Current Consensus is
The current consensus among 5 polled investment analysts is to buy stock in Inari Medical.
Inari Medical, Inc., a medical device company, develops, manufactures, markets, and sells devices for the interventional treatment of venous diseases in the United States. The company provides ClotTriever, a mechanical thrombectomy system, which is designed to core, capture, and remove large clots from large vessels, as well as for treatment of deep vein thrombosis; and FlowTriever, a large bore catheter-based aspiration and mechanical thrombectomy system, for treatment of pulmonary embolism. It also offers FlowSaver; FlowStasis, a large bore suture retention device designed to address various aspects of venous access site; and FlowTriever 2, a new disk shape designed to capture and remove wall adherent clot and shorten treatment. The company was formerly known as Inceptus Newco1 Inc. and changed its name to Inari Medical, Inc. in September 2013. Inari Medical, Inc. was incorporated in 2011 and is headquartered in Irvine, California.